OPERATIONAL EXCELLENCE IN CONTINUOUS, PHARMACEUTICAL MANUFACTURING
Pfizer began developed Portable Continuous Miniature Modular (PCMM) technology with the goal of accelerating its pharmaceutical portfolio through continuous manufacturing. As the PCMM progresses towards becoming the industry’s standard manufacturing platform, Pfizer recognizes the need to establish operational excellence within the PCMM. The ultimate goal is to enable Pfizer’s portfolio by increasing PCMM availability via operational excellence.
The Tauber team created an operational excellence framework and identified applicable metrics with which to analyze and measure the PCMM’s operational performance. The team then implemented a series of solutions and made long term recommendations to bridge operational gaps and increase operational excellence. Due to the work done by the Tauber team to improve communication, scheduling logic, and operational efficiency, Pfizer will save an estimated $5.85 million/year, and the PCMM will better enable Pfizer’s portfolio by supporting the development of two additional compounds per year.
Read the 2017 Pfizer Team Project Executive Summary in the 2017 SPOTLIGHT! book.
Robert Carsey –Master of Business Administration
Jurgen Kameniku–MSE Chemical Engineering
Rob Noack –Director, Drug Product Supply
Jessica Sigurdson–Technology Lead, Drug Product Supply
Paul Stuart –VP, Drug Product Supply
Eric Svaan–Ross School of Business
Henry Wang–College of Engineering
About Tauber Team Projects:
The 2017 Tauber Team Projects resulted in $575 million in savings according to sponsoring company calculations, an average of $18.5 million per project over 3 years.